Search

Governments should rethink strategies to prevent whooping cough in newborn infants, including booster vaccination of close contacts of the baby.

New collaborative research involving almost 600,000 pregnant mothers has demonstrated a dramatic increase in uptake of the whooping cough (pertussis) vaccine after identifying just 22 per cent of WA women had the maternal vaccination between 2012 – 2017.

Immunisation is the most effective way of protecting your child against a range of serious illnesses, including measles, hepatitis B and whooping cough. All vaccines used in Australia undergo stringent testing and ongoing monitoring.

Tiny babies could soon have much-needed protection from community transmission of potentially deadly whooping cough thanks to a world-first nasal spray vaccine being trialed at The Kids Research Institute Australia.

Whooping cough (pertussis) is a highly contagious respiratory infection which causes a severe cough and can be particularly dangerous to babies under a year old. Vaccination is the best way to reduce the risk of whooping cough.

Research by The Kids Research Institute Australia will soon ensure young children are better protected against whooping cough.

The Deborah Lehmann Research Award in Paediatric Infectious Disease Research is a funding mechanism to support the training and development of early- to mid-career researchers (EMCR) or Higher Degree by Research (HDR) students who are nationals from the Pacific Region working in or outside their hom

Ruth Peter Thornton Richmond PhD MBBS MRCP(UK) FRACP Co-head, Bacterial Respiratory Infectious Disease Group (BRIDG) Head, Vaccine Trials Group

Evidence suggests that children who had received an initial priming dose of whole-cell pertussis (wP) vaccine, rather than acellular pertussis (aP) vaccine, had a lower risk of developing IgE-mediated food allergy, the most common cause of anaphylaxis-related hospital presentations of childhood.

We compared the effect of a heterologous wP/aP/aP primary series (hereafter mixed wP/aP) versus a homologous aP/aP/aP primary schedule (hereafter aP-only) on antibody responses to co-administered vaccine antigens in infants and toddlers.